Read by QxMD icon Read

Leukemia & Lymphoma

Rudy Birsen, David Boutboul, Bruno Crestani, Agathe Seguin-Givelet, Claire Fieschi, Remi Bertinchamp, Mihaela Giol, Marion Malphettes, Eric Oksenhendler, Lionel Galicier
No abstract text is available yet for this article.
January 13, 2017: Leukemia & Lymphoma
Ting Wang, Peipei Xu, Fan Wang, Di Zhou, Ruju Wang, Li Meng, Xiaohui Wang, Min Zhou, Bing Chen, Jian Ouyang
Digoxin has potential antitumor properties. This study investigated whether digoxin suppressed Burkitt's lymphoma (BL) cells. Raji and NAMALWA cells were exposed to digoxin, followed by assay of cell viability, apoptosis and cell cycle. Western blotting was used to analyze NF-κB activity. A xenograft model was established for therapeutic efficacy evaluation. Digoxin inhibited cell growth and resulted in apoptosis and cell cycle arrest (G0/G1 for Raji cells; G2/M for NAMALWA cells). Digoxin inhibited DNA synthesis and induced morphological apoptotic characteristics...
January 13, 2017: Leukemia & Lymphoma
Yan Guo, Stephen A Strickland, Sanjay Mohan, Shaoying Li, Amma Bosompem, Kasey C Vickers, Shilin Zhao, Quanhu Sheng, Annette S Kim
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of the elderly that carry an increased risk of progression to acute myeloid leukemia (AML). Since small non-coding RNAs (sRNAs), including microRNA (miRNAs), act as regulators of cellular differentiation, we hypothesized that changes to sRNAs might be implicated in the progression of MDS to AML. We conducted sRNA sequencing on three sets of patients: Group A (MDS patients who never progressed to AML); Group B (MDS patients who later progressed to an AML); and Group C (AML patients with myelodysplasia-related changes, including patients with a known preceding diagnosis of MDS)...
January 13, 2017: Leukemia & Lymphoma
Christine Greil, Chrissoula Kiote-Schmidt, Geertje Fink, Gabriele Ihorst, Steffi Hildenbeutel, Roland Bosse, Justus Duyster, Monika Engelhardt, Ralph Wäsch
Plerixafor, although costly, is added to mobilizing chemotherapy and G-CSF to overcome poor stem cell mobilization. We demonstrate that it can be safely administered mostly once as a single dose in preemptive and rescue settings, leading to apheresis yields of >2 and >4×10(6) CD34 + cells/kg body weight (bw) in 83% and 48%, respectively. Of note, 35/46 (76%) patients showed a substantial benefit with increased peripheral blood (PB) CD34 + cells prior to apheresis (8.84 vs. 1.72/μl, p < ...
January 13, 2017: Leukemia & Lymphoma
Luke F Peterson, Miao-Chia Lo, Yihong Liu, Diane Gianolla, Emilija Mitrikeska, Nicholas J Donato, Craig N Johnson, Shaomeng Wang, Jessica Mercer, Moshe Talpaz
Chronic myeloid leukemia (CML) is characterized by the chromosomal translocation 9;22, known as the Philadelphia chromosome (Ph), which produces the BCR-ABL fusion tyrosine kinase. Although well-managed by BCR-ABL tyrosine kinase inhibitors (TKIs), treatment fails to eliminate Ph + primitive progenitors, and cessation of therapy frequently results in relapse. The p53 protein is an important regulator of cell cycle and apoptosis. The small molecules MI-219 target the interaction between p53 and its negative regulator HDM2, leading to its stabilization and activation...
January 13, 2017: Leukemia & Lymphoma
Gunjan L Shah, Heather Landau, Dory Londono, Sean M Devlin, Satyajit Kosuri, Alexander M Lesokhin, Nikoletta Lendvai, Hani Hassoun, David J Chung, Guenther Koehne, Suresh C Jhanwar, Ola Landgren, Ross Levine, Sergio A Giralt
We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having ≥ VGPR and 20% achieving a CR, similar to non +1q patients (p = .64). The median PFS from diagnosis with +1q was 2.1 years (95% CI: 1.2-not reached (NR)) vs 4.3 years (95% CI: 3...
January 12, 2017: Leukemia & Lymphoma
Jenna D Goldberg, Junting Zheng, Ravin Ratan, Trudy N Small, Kuan-Chi Lai, Farid Boulad, Hugo Castro-Malaspina, Sergio A Giralt, Ann A Jakubowski, Nancy A Kernan, Richard J O'Reilly, Esperanza B Papadopoulos, James W Young, Marcel R M van den Brink, Glenn Heller, Miguel-Angel Perales
Infection, relapse, and GVHD can complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the effect of poor immune recovery on infection risk is well-established, there are limited data on the effect of immune reconstitution on relapse and survival, especially following T-cell depletion (TCD). To characterize the pattern of immune reconstitution in the first year after transplant and its effects on survival and relapse, we performed a retrospective study in 375 recipients of a myeloablative TCD allo-HSCT for hematologic malignancies...
January 10, 2017: Leukemia & Lymphoma
Masahiko Sumi, Keijiro Sato, Hiroko Kaiume, Wataru Takeda, Takehiko Kirihara, Toshimitsu Ueki, Yuki Hiroshima, Hikaru Kobayashi
No abstract text is available yet for this article.
December 21, 2016: Leukemia & Lymphoma
Jonathan J Hogan, Alison W Loren, Matthew G Denker, James K Mangan
No abstract text is available yet for this article.
December 21, 2016: Leukemia & Lymphoma
Xiaojun Xia, Yun Duan, Jie Cui, Junfeng Jiang, Li Lin, Xiaojuan Peng, YuHong Wang, Bingtao Guo, Shouhai Liu, Xudong Lei
The aim of this study was to investigate the association of methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and additional gene-gene interaction with acute lymphoblastic leukemia (ALL) risk. Logistic regression was performed to investigate the association between two single nucleotide polymorphisms (SNPs) within MTHFR gene and ALL risk and additional gene-gene interaction between rs1801133 and rs1801131. The minor allele of rs1801133 and rs1801131 is associated with decreased ALL risk, OR (95% CI) were 0...
December 20, 2016: Leukemia & Lymphoma
Linda B Baughn, Zohar Sachs, Klara E Noble-Orcutt, Amit Mitra, Brian G Van Ness, Michael A Linden
Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment failure due to drug resistance occurs. Bz-sensitive and -resistant MM cells have distinct immunophenotypic signatures that correlate with clinical outcome. These changes can be identified by fluorescence-based cytometry (FBC), however, FBC is rarely used in predicting Bz resistance. Mass cytometry (MC) is a recently developed variation of flow cytometry that detects heavy metal-ion tagged antibodies using time-of-flight mass spectrometry allowing for detection of up to 38 epitopes simultaneously in a single cell, without significant overlap, exceeding the dimensionality of FBC 3-4-fold...
December 16, 2016: Leukemia & Lymphoma
Vicki A Morrison, Edie A Weller, Thomas M Habermann, Shuli Li, Richard I Fisher, Bruce D Cheson, Bruce A Peterson
Patterns of myeloid growth factor (GF) usage and febrile neutropenia (FN) were examined in patients >60 years of age with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) enrolled on CALGB 9793/ECOG-SWOG 4494, receiving initial therapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or rituximab + CHOP (R-CHOP). Myeloid GFs were administered to 256/520 (49%) patients. Indications for use were: prevent dose reduction/dose delay (81%, 207/256); treat FN or non-febrile neutropenia (NFN) (19%, 48/256)...
December 14, 2016: Leukemia & Lymphoma
Ling Zhang, Kathy L McGraw, David A Sallman, Alan F List
TP53 gene mutations occurring in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are associated with high-risk karyotypes including 17p abnormalities, monosomal and complex cytogenetics. TP53 mutations in these disorders portend rapid disease progression and resistance to conventional therapeutics. Notably, the size of the TP53 mutant clone as measured by mutation allele burden is directly linked to overall survival (OS) confirming the importance of p53 as a negative prognostic variable...
December 14, 2016: Leukemia & Lymphoma
Nivedita Kuila, Kasturi Bala Nayak, Arundhati Halder, Subramaniam Agatheeswaran, Ghanashyam Biswas, Sutapa Biswas, Naresh Chandra Pattnayak, Soumen Chakraborty
Although BCR-ABL is the hallmark genetic abnormality of chronic myeloid leukemia (CML), secondary molecular events responsible for the evolution of the disease to blast crisis are yet to be deciphered. Taking into account the significant association of ecotropic viral integration site I (EVI1) in CML drug resistance, it is necessary to decipher the other roles played by EVI1 in CML disease progression. In this regard, we cross-hybridized three microarray datasets and deduced a set of 11 genes that seems to be regulated by EVI1 in CML...
December 14, 2016: Leukemia & Lymphoma
Dimitrios C Ziogas, Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Magdalini Migkou, Maria Gavriatopoulou, Despoina Spanomichou, Evangelos Eleutherakis-Papaiakovou, Despoina Fotiou, Ioannis Panagiotidis, Eftychia Kafantari, Erasmia Psimenou, Ioannis Boletis, Demetrios V Vlahakos, Hariklia Gakiopoulou, Charis Matsouka, Meletios A Dimopoulos
Monoclonal immunoglobulin deposition disease (MIDD) is characterized by non-organized immunoglobulin-fragments along renal basement membranes with subsequent organ deterioration. Treatment is directed against the immunoglobulin-producing clone. We treated 18 MIDD patients with bortezomib-based regimens (12 received bortezomib-dexamethasone, 6 bortezomib-dexamethasone with cyclophosphamide). Eleven (61%) patients achieved a hematologic response, but only 6 (33.3%) reached to a complete (CR) or very good partial response (VGPR)...
December 14, 2016: Leukemia & Lymphoma
Karthik V Giridhar, Tait Shanafelt, Pritish K Tosh, Sameer A Parikh, Timothy G Call
No abstract text is available yet for this article.
December 14, 2016: Leukemia & Lymphoma
Yasuyuki Arai, Tomoyasu Jo, Hiroyuki Matsui, Tadakazu Kondo, Akifumi Takaori-Kondo
The efficacy of rabbit antithymocyte globulin (ATG) for the prevention of graft-versus-host disease (GVHD) has been evaluated in several randomized control trials, but the results show some discrepancies. Therefore, we performed a systematic review and meta-analysis covering the latest RCTs including six trials (total 845 patients). The incidence of acute and chronic GVHD was significantly lower in the ATG arms (risk ratio, 0.75 and 0.54, respectively). No significant differences were found regarding overall survival, the incidence of relapse, and non-relapse mortality; however, the incidence of cytomegalovirus and Epstein-Barr virus reactivation increased (risk ratio, 1...
December 12, 2016: Leukemia & Lymphoma
Han Yan, Dao-Yu Zhang, Xi Li, Xiao-Qing Yuan, Yong-Long Yang, Ke-Wei Zhu, Hui Zeng, Xiao-Lin Li, Shan Cao, Hong-Hao Zhou, Wei Zhang, Xiao-Ping Chen
Whether long non-coding RNA (lncRNA) single-nucleotide polymorphisms (SNPs) affect prognosis of acute myeloid leukemia (AML) remains unknown. To search the association between lncRNA SNPs and AML outcomes, thirty tagSNPs in five lncRNAs were genotyped in 313 AML patients. Survival analysis indicated that GAS5 rs55829688 (T > C) was significantly associated with prognosis of AML (p = 0.018). Patients with rs55829688 CC genotype showed higher GAS5 expression in peripheral blood mononuclear cells (PBMCs) (p = 0...
December 12, 2016: Leukemia & Lymphoma
Jose F Falantes, Francisco J Márquez-Malaver, Teresa Knight, Cristina Calderón-Cabrera, María L Martino, Jose González, Isabel Montero, Ildefonso Espigado, Jose A Pérez-Simón
Chronic medical diseases, evaluated by several comorbidities indexes have been reported to influence on overall survival in patients with myelodysplastic syndrome (MDS). However, these studies included patients with lower and higher-risk disease by IPSS. This study retrospectively evaluates the role of comorbidities (evaluated by the MDS comorbidity index; MDS-CI) together with clinical parameters in a series of 232 patients with LR-MDS (defined as either an IPSS score of low/intermediate-1 and favorable cytogenetic categories by IPSS-R)...
December 12, 2016: Leukemia & Lymphoma
Ming-Hsun Bryan Keng, Hui-Lin Clara Keng, Ban-Hock Tan, Gee-Chuan Wong
No abstract text is available yet for this article.
December 8, 2016: Leukemia & Lymphoma
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"